Trump blasts Big Phar­ma again — “some­body’s get­ting very rich” — and promis­es drug price leg­is­la­tion

On Mon­day Eli Lil­ly CEO Dave Ricks out­lined his com­pa­ny’s case that their drug prices are not spin­ning out of con­trol. In a lengthy re­port he as­sert­ed that dis­counts on drug prices to phar­ma ben­e­fit man­agers has grown from 28% in 2012 to an av­er­age of 50% last year. And while list prices grew 14% last year, net prices ac­tu­al­ly grew by on­ly 2.4%.

That po­si­tion re­flect­ed a grow­ing ef­fort on Big Phar­ma’s part — a de­fen­sive re­ac­tion that al­so in­cludes two oth­er US-based phar­ma gi­ants, Mer­ck and J&J — to de­fend it­self against grow­ing pres­sure from the Trump ad­min­is­tra­tion to rein in drug prices.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.